New York State Biodefense Commercialization Fund

There are presently no open calls for submissions.

New York State Biodefense Commercialization Fund

Following is an overview of the Biodefense Commercialization Fund program and requirements. More details can be found by reading the Biodefense Commercialization Fund Guidelines.  

Short Proposals are due Thursday, October 6th at 5:00PM ET

The Program Overview:

The $40 million Biodefense Commercialization Fund is intended to encourage and accelerate focuses on encouraging and accelerating the development and commercialization of solutions for serious infectious disease threats, including COVID-19 and its variants, while fostering the creation of new life science businesses and supporting industry growth.

Areas of Interest:

Applications for all therapeutic, diagnostic, digital epidemiology, and pathogen surveillance projects with a translational/commercialization trajectory are encouraged.  Special consideration may be given to small molecule therapeutics and novel platform diagnostics targeting COVID, its variants, or other infectious disease threats.


  • Incorporated Startup companies based in New York State that have recently raised or are in the process of raising Seed, Series A, or Series B funding
  • Incorporated Startup companies from outside of New York State that meet the above qualifications and intend to relocate to New York State
  • New York-based academic institutions developing advanced IP and translational innovations that are on the cusp of moving into a commercial development phase


  • Incorporated Startup Companies are eligible to receive between $1 Million - $4 Million in award funding (grants $2M or more will require matching funds).
  • Academic Institutions are eligible to receive between $250K - $500K in award funding

Application Review Criteria

Applications will be reviewed by an expert review panel based on the following criteria:

  • Innovation & Value Proposition
  • Intellectual Property
  • Team Experience & Capabilities
  • Approach & Feasibility of technology
  • Relevance and Applicability to Future Infectious Disease Threats


Please e-mail

New York State Biodefense Commercialization Fund